This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: K22.0 | Special Copayment Reduction: V315 |
| B. Synonyms | — |
| C. Adult onset | Likelihood of first presentation in adulthood: high — achalasia occurs most often in adults aged 25~60, with a median age of onset in the 40s. Pediatric onset is rare, accounting for less than about 5% of all cases. It also occurs in the elderly, and there is almost no sex difference. |
| 1. History | 1672 first description by Thomas Willis (dilation with whalebone) → 1881 use of the term achalasia → 1914 Heller myotomy → 1958 standardization of pneumatic dilation by Vantrappen → 2010s development of POEM (peroral endoscopic myotomy) → current diagnosis based on the Chicago Classification. |
| 2. Causes | Cause unknown (mostly idiopathic). Loss of inhibitory neurons (NO·VIP-secreting neurons) in the lower esophageal sphincter (LES) and esophageal body is central. Hypotheses of autoimmune ganglionitis, viral infection (HSV, measles), and genetic predisposition. Secondary forms (Chagas disease, gastric cancer invasion) require separate differentiation. |
| 3. Genetics | Mostly sporadic. Some familial achalasia (1~2% of all cases) has been reported, and there are studies of HLA association (HLA-DQ1). Allgrove syndrome (AAA syndrome): AAAS gene (12q13.13) variants, autosomal recessive. Increased risk of achalasia in association with Down syndrome has been reported. |
| 4. General epidemiology | Annual incidence about 1~3 per 100,000. Prevalence about 10 per 100,000. No sex difference. Age of onset 25~60 years. Occurs worldwide with no racial difference. Steady increase in registered patients in Korean health insurance data as well. Special Copayment Reduction V315. |
| 5. Pathophysiology | Selective loss of inhibitory neurons (NO·VIP-secreting) in Auerbach's plexus → impaired LES relaxation → loss of esophageal body peristalsis → functional esophageal obstruction → food stasis and esophageal dilation → regurgitation and aspiration → chronic esophageal mucosal injury and increased cancer risk. |
| 6. Symptoms | Dysphagia (to both solids and liquids), regurgitation (of undigested food), chest pain (60~80%), weight loss. Average delay of 2~4 years from symptom onset to diagnosis. Nocturnal cough and aspiration pneumonia may accompany. |
| 7. Signs | Chest X-ray: widened esophageal shadow, absent gastric air bubble. Esophagography: bird's beak appearance (bird-beak sign), dilated esophagus. Esophageal manometry (HRM): impaired LES relaxation (elevated IRP) and absent peristalsis are the diagnostic criteria. Endoscopy: resistance at the cardia, food stasis. |
| 8. Screening | No population screening. Immediate upper endoscopy and esophagography in patients with persistent dysphagia. High-resolution esophageal manometry (HRM) is key to confirmation. Endoscopy and CT to exclude secondary forms (neoplastic achalasia). |
| 9. Diagnosis | High-resolution esophageal manometry (HRM): distinguishes Type I (aperistaltic), II (panesophageal pressurization), and III (spastic) by Chicago Classification v4.0 criteria. Esophagography: bird's beak appearance. Upper endoscopy: confirm resistance at the cardia + exclude secondary causes. Treatment response followed with timed barium esophagram. |
| 10. Treatment | Definitive treatment: Heller myotomy (laparoscopic), POEM (peroral endoscopic myotomy). Nonsurgical: pneumatic dilation. Medications: calcium channel blockers, nitrates, botulinum toxin LES injection (short-term effect). Choice of treatment determined by Type, age, and patient preference. |
| 11. Prognosis | 5-year success rate of Heller myotomy about 85~90%. POEM has a similar short-term success rate but higher reflux complications. 5-year success rate of pneumatic dilation about 60~80%. Risk of esophageal cancer (squamous cell carcinoma) increases about 10-fold after treatment, so long-term endoscopic follow-up is essential. |
| 12. Prevention | No specific prevention. Early diagnosis to limit progression of esophageal dilation. Regular follow-up after treatment (esophageal cancer screening). Reflux management (concurrent antireflux therapy). Aspiration prevention (maintain upright posture after meals, limit eating before bedtime). |
| 13. References | Richter JE. Achalasia. GI Motility online. 2006 … and 9 other references |
The history of achalasia dates back to the 17th century. In 1672, the English physician Thomas Willis first described treating a patient suffering from dysphagia with a dilator made of whalebone. This was a primitive form of modern pneumatic dilation; although the mechanism was unknown at the time, it is presumed to have had the effect of mechanically dilating the lower esophageal sphincter.
In the 19th and early 20th centuries, understanding of the pathophysiology of this disease gradually increased. In 1881, Einhorn of Germany used the term 'Cardiospasmus,' and as it gradually became known that this condition was due not to muscle spasm but to a neural abnormality, the more accurate term 'achalasia' (failure to relax, from Greek a = without + chalasis = relaxation) emerged.
The most important event in the history of treatment was the first esophageal myotomy performed by Ernst Heller of Germany in 1914. Heller originally performed both anterior and posterior myotomies, but Zaaijer later refined it to a single myotomy (anterior only), laying the foundation for the current Heller myotomy. This operation has remained the definitive surgery for achalasia for more than 100 years.
In 1958, Vantrappen and Hellemans standardized pneumatic dilation, offering an alternative to surgical treatment. In the 1980s, injection of botulinum toxin (botulinum toxin A) into the lower esophageal sphincter was introduced as a noninvasive treatment with short-term effect. In 1991, laparoscopic Heller myotomy was introduced, greatly reducing the invasiveness of open surgery.
The most recent innovation is Per-Oral Endoscopic Myotomy (POEM), developed by Inoue et al. in Japan in 2010. In this method, a submucosal tunnel is created endoscopically in the esophagus and the lower esophageal muscle layer is incised; because it can be performed without an abdominal wall incision, it has spread rapidly worldwide. Currently, High-Resolution Manometry (HRM) based on the Chicago Classification v4.0 (2021) is used as the diagnostic standard, subdividing achalasia into Type I, II, and III for use in treatment selection.
The cause of achalasia has not yet been fully elucidated, and idiopathic cases account for the majority. The main hypotheses regarding its pathogenesis are as follows.
Neuronal loss hypothesis: The core lesion of achalasia is the selective loss of inhibitory neurons in Auerbach's plexus (myenteric plexus) within the lower esophageal sphincter (LES) and esophageal body. These neurons secrete nitric oxide (NO) and vasoactive intestinal peptide (VIP) to mediate LES relaxation. When inhibitory neurons are damaged, the LES does not relax sufficiently even during swallowing, and peristalsis of the esophageal body is lost. In contrast, excitatory neurons (cholinergic neurons) are relatively preserved, resulting in LES hypertension.
Autoimmune ganglionitis hypothesis: T-lymphocyte infiltration of Auerbach's plexus is observed in patients with achalasia, and anti-ganglionic antibodies are detected in some patients. An association with HLA-DQ1 and cross-reactivity to certain viral antigens have been suggested, leading to the hypothesis that autoimmune ganglionitis due to molecular mimicry is the cause.
Viral infection hypothesis: There is a hypothesis that herpes simplex virus type 1 (HSV-1), measles virus, varicella-zoster virus (VZV), and others may cause neuronal damage through an immune response after latent infection of Auerbach's plexus. However, direct evidence establishing a causal relationship between infection and achalasia is still lacking.
Secondary achalasia (pseudoachalasia): Findings similar to achalasia may arise from local invasion by esophagogastric junction adenocarcinoma (cancer of the gastric cardia or lower esophagus), lymphoma, or lung cancer, or from paraneoplastic neuropathy (pseudoachalasia). In Central and South America, Trypanosoma cruzi infection (Chagas disease) destroys the plexus and causes secondary achalasia.
Achalasia occurs mostly sporadically and is understood to have a multifactorial predisposition rather than being a single-gene disorder. Familial achalasia accounts for only about 1~2% of all cases, and in these cases autosomal dominant or recessive inheritance patterns are rarely reported.
HLA association: Studies have shown that the frequency of HLA-DQ1 (especially DQA1*0103 and DQB1*0603) is higher in patients with achalasia than in normal controls. This supports the autoimmune pathogenesis hypothesis and suggests that genetic predisposition may determine the direction of the immune response. However, HLA association alone does not cause achalasia; interaction with environmental triggers appears to be necessary.
Allgrove syndrome (AAA syndrome): This is a rare case in which achalasia appears as part of a hereditary syndrome. AAA syndrome is characterized by the triad of adrenocorticotropic hormone (ACTH)-resistant adrenal insufficiency, achalasia, and alacrima (deficient tear secretion), and is an autosomal recessive disorder caused by pathogenic variants in the AAAS gene (12q13.13). The AAAS gene encodes ALADIN, a component protein of the nuclear pore complex, and is involved in neural development and autonomic function. It is often diagnosed first through alacrima in childhood, with achalasia appearing later.
The co-occurrence of Down syndrome (trisomy 21) and achalasia is reported at a higher frequency than in the general population. Abnormal development of the autonomic nervous system has been proposed as the mechanism. In addition, esophageal motility disorders similar to achalasia may accompany some hereditary autonomic disorders, Parkinson's disease, and multiple system atrophy. In adult-onset achalasia with a family history, gene panel testing (especially autonomic-related genes such as AAAS) may be considered.
Achalasia is a rare esophageal motility disorder; based on Western studies, the annual incidence is reported to be about 1~3 per 100,000 population, and the prevalence about 10 per 100,000. Incidence varies by region, and systematic epidemiological data from Asian countries are scarcer than in the West.
Sex and age distribution: There is almost no difference in prevalence between men and women; the main range of age at onset is 25~60 years, with the highest frequency in the 40s. Onset in children and adolescents is rare, accounting for less than about 5% of all cases, and it also occurs in the elderly. It occurs evenly worldwide without racial or geographic differences.
Changes in incidence: The diagnosis rate of achalasia has been reported to be increasing over recent decades, which can be seen as reflecting improved diagnostic sensitivity due to the spread of HRM (high-resolution esophageal manometry). It is difficult to distinguish whether this is a change in actual incidence or an improvement in diagnosis rate.
Secondary achalasia: About 2~4% of patients diagnosed with achalasia actually have neoplastic pseudoachalasia. Therefore, exclusion of secondary causes is essential in elderly patients aged 55 or older, with rapid weight loss (7 kg or more within 6 months), or when diagnosed within 1 year of symptom onset. In South America, secondary achalasia due to Chagas disease is an important cause.
Epidemiology in Korea: In Korea, achalasia is a disease eligible for registration for rare disease Special Copayment Reduction (V315). Domestic epidemiological research is limited, but studies based on Health Insurance Review & Assessment Service (HIRA) data report a steadily increasing number of registered patients. Domestic studies also recognize achalasia as an important differential diagnosis in patients presenting with dysphagia as the chief complaint.
The core pathophysiology of achalasia is attributed to the selective loss of inhibitory neurons in the esophageal Auerbach's plexus (myenteric plexus). In normal esophageal motility, swallow-associated relaxation of the lower esophageal sphincter (LES) is mediated by nitric oxide (NO) and vasoactive intestinal peptide (VIP) secreted from inhibitory neurons.
In achalasia, when inhibitory neurons are selectively lost through inflammatory injury, autoimmune attack, or other mechanisms, LES relaxation is insufficient or does not occur at all. In contrast, excitatory cholinergic neurons (acetylcholine-secreting) are relatively preserved, so the baseline pressure of the LES remains abnormally high. This imbalance results in the 'failure to relax' of the LES.
Loss of peristalsis in the esophageal body: Loss of inhibitory neurons in Auerbach's plexus occurs not only in the LES but also in the esophageal body, so normal peristalsis is lost. In the Chicago Classification, in Type I (aperistaltic) the esophageal body does not contract at all, in Type II (panesophageal pressurization) abnormal pressure increases occur throughout the esophagus with each swallow, and Type III (spastic) is characterized by premature and spastic contractions.
Esophageal dilation and food stasis: Due to impaired LES relaxation, ingested food cannot pass into the stomach and stagnates in the esophagus, so the esophagus gradually dilates. Bacterial fermentation and inflammation caused by food stasis damage the esophageal mucosa, and chronic inflammation can progress through dysplasia to squamous cell carcinoma. In particular, in patients with severe esophageal dilation and long disease duration, the risk of esophageal cancer increases about 10-fold compared with the general population.
Regurgitation and aspiration: Despite impaired LES relaxation, food may partially regurgitate due to gravity and pressure, or regurgitated contents may be aspirated into the airway during coughing or retching. This causes aspiration pneumonia, bronchitis, and chronic cough.
Symptoms of achalasia progress gradually, and an average symptom delay of 2~4 years before diagnosis is reported. This is because the symptoms are nonspecific and are often misdiagnosed as gastroesophageal reflux disease (GERD) or functional digestive disorders.
Dysphagia is the most common and characteristic symptom, occurring in more than 90% of patients with achalasia. It is characterized by difficulty swallowing liquids as well as solid food, which is important for differentiating it from purely mechanical obstruction (tumor, stricture). Dysphagia appears intermittently and then worsens persistently as the disease progresses. Hot or cold drinks and stress may worsen symptoms.
Regurgitation is the second most common symptom, in which undigested food or saliva regurgitates into the mouth. This is a neutral rather than acidic regurgitation—regurgitation not of gastric contents but of contents stagnant in the esophagus. Regurgitation is worsened by changes in posture (bending forward, lying down). Nocturnal regurgitation causes aspiration during sleep and may cause chronic cough and aspiration pneumonia.
Chest pain occurs in about 60~80% of patients with achalasia and presents as retrosternal or central chest pressure or squeezing pain. Because chest pain resembles cardiac chest pain, unnecessary tests are often performed to rule out heart disease. Chest pain is more prominent in Type III (spastic) achalasia.
Weight loss: Weight decreases due to reduced food intake from dysphagia, and nutritional deficiency may develop. Rapid weight loss (7 kg or more within a short period) strongly suggests neoplastic pseudoachalasia, so immediate further testing is needed.
Inability to belch: Some patients complain that they cannot belch because the gastroesophageal junction is always closed and gas in the stomach cannot pass back into the esophagus. This is a relatively specific symptom of achalasia.
Physical signs of achalasia may be nonspecific or absent early on, but as the disease progresses, various test findings appear.
Plain chest X-ray: Widening of the upper mediastinal shadow due to esophageal dilation and absence or reduction of the gastric air bubble may be observed. An air-fluid level may be seen in a severely dilated esophagus. Lung infiltrates due to aspiration pneumonia may accompany.
Barium esophagram: Abrupt narrowing of the lower esophagus with dilation of the esophagus above it forms a bird's beak appearance (bird-beak sign). This is the typical radiographic finding of achalasia. The Rezende classification (grades I~IV), which classifies the degree of esophageal dilation, is used to predict treatment outcomes. Timed barium esophagram (TBE) provides an objective measure for following treatment response.
Upper endoscopy: Dilation of the esophageal body, stasis of food and saliva, and resistance to passage through the cardia (a sense of resistance on scope insertion, followed by a sudden 'pop' sensation of passage) are characteristic. It is essential for excluding esophagogastric junction tumors and mucosal abnormalities.
High-resolution esophageal manometry (HRM): This is the key test for diagnosing achalasia. According to the Chicago Classification v4.0, achalasia is classified as follows: Type I (classic/non-vigorous): impaired LES relaxation (IRP ≥15 mmHg) + absent esophageal body pressure; Type II (pan-esophageal pressurization): impaired LES relaxation + panesophageal pressurization (>30 mmHg) in ≥20% of swallows; Type III (spastic): impaired LES relaxation + premature or spastic contractions in ≥20% of swallows. IRP (Integrated Relaxation Pressure) ≥15 mmHg (supine) is the key criterion for impaired LES relaxation.
There is no screening program for achalasia in the general population. It is important to perform appropriate tests in a timely manner in patients complaining of dysphagia, as diagnostic delay increases the progression of esophageal dilation and complications.
Systematic approach in patients with dysphagia: In all patients with dysphagia persisting for 3 months or longer, immediate upper endoscopy is performed to first exclude mechanical obstruction (cancer, stricture, external compression). If upper endoscopy is normal or a functional cause is suspected, a barium esophagram is performed, and the diagnosis is then confirmed with high-resolution esophageal manometry (HRM).
Elderly patients aged 55 or older: Because neoplastic pseudoachalasia is more frequent, even if HRM shows achalasia findings, esophagogastric junction tumors and mediastinal lymphadenopathy must be excluded with endoscopic ultrasound (EUS), abdominal and chest CT, or PET-CT.
Children with suspected Allgrove syndrome: When achalasia is diagnosed in a child, alacrima (dry eyes) and adrenal insufficiency (hypoglycemia, hypotension, hyperpigmentation, etc.) are evaluated together to exclude Allgrove syndrome. AAAS gene testing is decisive for diagnosis.
Follow-up screening after treatment: In patients treated for achalasia, if symptoms persist or recur, treatment response is objectively evaluated with HRM and TBE. Because the risk of esophageal cancer (squamous cell carcinoma) is increased in patients with achalasia, some experts recommend regular endoscopic surveillance every 3~5 years.
Confirmation of achalasia centers on high-resolution esophageal manometry (HRM), and a stepwise approach that excludes secondary causes with esophagography and upper endoscopy is the standard.
Upper endoscopy: As the first step of diagnosis, it excludes mechanical causes (tumor, inflammatory stricture, Schatzki ring) and causes of secondary achalasia (esophagogastric junction cancer). If upper endoscopy shows resistance to passage through the cardia but no tumor, and the esophageal mucosa is relatively normal, achalasia is likely.
Barium esophagram: Bird's beak narrowing, esophageal dilation, and delayed passage of contrast during swallowing are characteristic. TBE (timed barium esophagram) measures the height of contrast remaining after 5 minutes and is used for objective comparison before and after treatment.
High-resolution esophageal manometry (HRM): This is the key to confirming achalasia. By Chicago Classification v4.0 criteria, achalasia is diagnosed when IRP ≥15 mmHg + absence of normal peristalsis are met. The distinction among Types I, II, and III is related to treatment prognosis, with Type II reported to have the best treatment response and Type III the worst. Because IRP criteria may differ in the upright position, measurement in each position is recommended.
Endoscopic ultrasound (EUS) and CT: Essential for excluding neoplastic achalasia. They evaluate submucosal tumors, lymphadenopathy, and extrinsic compression around the esophagogastric junction.
FLIP (Functional Lumen Imaging Probe): A new technology that measures the distensibility of the esophagogastric junction with a balloon catheter in the esophagus, used as a complementary diagnostic tool when conventional HRM is diagnostically uncertain. By directly measuring the mechanical compliance of the LES, it helps differentiate functional impaired relaxation from mechanical obstruction.
The goal of achalasia treatment is to relieve the functional obstruction caused by impaired LES relaxation, improving esophageal emptying and relieving symptoms. Currently there is no treatment that regenerates the lost neurons, so all treatments aim to relieve symptoms and prevent disease progression.
Laparoscopic Heller Myotomy (LHM): An operation in which the muscle layer of the LES and lower esophagus is incised longitudinally using a laparoscope. The standard is a myotomy of about 7~8 cm (6 cm on the esophageal side + 1.5~2 cm on the gastric side) combined with Dor or Toupet fundoplication to prevent gastroesophageal reflux. The 5-year success rate is about 85~90%, with excellent long-term efficacy.
Peroral endoscopic myotomy (POEM): An endoscopic treatment in which a tunnel is created in the esophageal submucosa with an endoscope passed through the mouth, and the LES muscle layer is then incised with endoscopic instruments. It can be performed without an abdominal wall incision, and studies show that, particularly in Type III (spastic) achalasia, it allows a longer myotomy and gives better results than LHM. However, because gastroesophageal reflux occurs in about 20~40% after POEM, long-term proton pump inhibitor (PPI) use is necessary.
Pneumatic Dilation (PD): A method in which a balloon catheter is positioned at the LES under radiographic or endoscopic guidance and inflated to mechanically dilate the LES. Standard balloon diameters of 30~35 mm are used, with stepwise increases in size. The 5-year success rate is about 60~80%, and the main complication is esophageal perforation (1~5%). It is particularly effective in Type II.
Botulinum toxin injection: Botulinum toxin A is injected into the LES under endoscopy to block the excitatory cholinergic neurons of the LES. Because of its low invasiveness, it is chosen for elderly patients and those at high surgical risk. The duration of effect is short, at 6~12 months, so repeated procedures are needed and long-term efficacy is inferior. Repeated procedures may reduce the effectiveness of subsequent myotomy.
Medication: Calcium channel blockers (sublingual nifedipine) and nitrates (isosorbide dinitrate) can temporarily lower LES pressure, but their effect is weak and side effects such as headache and hypotension are common. They are used only for short-term symptom relief while waiting for a procedure or surgery.
Achalasia cannot be cured with current treatments, but with appropriate treatment most patients can achieve long-term symptom relief and functional improvement. Treatment outcomes vary depending on the Chicago Classification Type of achalasia, the treatment method, and the degree of esophageal dilation.
Success rates of surgical and endoscopic treatment: The short-term (1~2 years) success rate of laparoscopic Heller myotomy is about 90~95%, and the 5-year success rate is about 85~90%. POEM has a short-term success rate similar or superior to LHM, but long-term data are still accumulating. The 5-year success rate of pneumatic dilation is about 60~80%, lower than surgery, but success can be maintained with repeated procedures. Type II achalasia tends to have the best treatment response and Type III the worst.
Reflux complications: The incidence of gastroesophageal reflux after POEM is higher than after LHM (about 20~40% vs 10~20%), with resulting risks of reflux esophagitis, Barrett's esophagus, and esophageal stricture. Long-term PPI use and regular endoscopic follow-up are recommended.
Increased risk of esophageal cancer: In patients with achalasia, the risk of squamous cell carcinoma increases about 10~16-fold compared with the general population. This is explained by the involvement of food stasis, chronic inflammation, and nitrosamine production from bacterial fermentation. The risk is higher in severe patients whose esophageal dilation persists even after treatment. Some experts recommend regular endoscopic surveillance every 3~5 years.
Quality of life: After successful treatment, dysphagia, regurgitation, and chest pain are markedly reduced, greatly improving quality of life. Even patients who had severe dysphagia and weight loss before treatment can resume a normal diet and regain weight after treatment.
There is no specific method to prevent the development of achalasia. However, after diagnosis, active treatment and follow-up make it possible to prevent complications and maintain quality of life.
Limiting progression through early diagnosis: Starting accurate diagnosis and treatment early after symptom onset can limit the progression of esophageal dilation. In a severely dilated esophagus (Rezende grade IV, sigmoid esophagus), the effectiveness of myotomy is reduced, so early treatment is important.
Aspiration prevention: Eat food in small portions slowly, maintain an upright posture for at least 30 minutes after meals, and avoid eating within 3 hours before bedtime. Sleeping with the head elevated helps prevent aspiration of regurgitated contents.
Reflux management after treatment: Particularly when gastroesophageal reflux develops after POEM or Heller surgery, it can progress to reflux esophagitis, Barrett's esophagus, and esophageal cancer, so PPIs are taken continuously and follow-up is done with regular endoscopy.
Early detection of esophageal cancer: Because the risk of esophageal cancer is increased in patients with achalasia, surveillance of the esophageal mucosa for abnormalities with regular endoscopy every 3~5 years is recommended. If rapid worsening of dysphagia, new chest pain, or weight loss occurs, further testing is performed immediately.
Nutritional management: When dietary restriction due to dysphagia persists, high-calorie, soft diet adjustment through dietitian consultation is helpful. In cases of severe malnutrition, temporary endoscopic esophageal dilation or percutaneous gastrostomy (PEG) may be needed before treatment.
Vaezi MF, Pandolfino JE, Vela MF. ACG clinical guideline: diagnosis and management of achalasia. Am J Gastroenterol. 2013;108(8):1238-1249. DOI: 10.1038/ajg.2013.196. PMID: 23877351.
Pandolfino JE, Kwiatek MA, Nealis T, Bulsiewicz W, Post J, Kahrilas PJ. Achalasia: a new clinically relevant classification by high-resolution manometry. Gastroenterology. 2008;135(5):1526-1533. DOI: 10.1053/j.gastro.2008.07.022. PMID: 18722376.
Boeckxstaens GE, Annese V, des Varannes SB, et al. Pneumatic dilation versus laparoscopic Heller myotomy for idiopathic achalasia. N Engl J Med. 2011;364(19):1807-1816. DOI: 10.1056/NEJMoa1010502. PMID: 21561346.
Inoue H, Minami H, Kobayashi Y, et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy. 2010;42(4):265-271. DOI: 10.1055/s-0029-1244080. PMID: 20354937.
Werner YB, Hakanson B, Martinek J, et al. Endoscopic or surgical myotomy in patients with idiopathic achalasia (ESCAPE). N Engl J Med. 2019;381(23):2219-2229. DOI: 10.1056/NEJMoa1905380. PMID: 31800987.
Kahrilas PJ, Bredenoord AJ, Fox M, et al. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil. 2015;27(2):160-174. DOI: 10.1111/nmo.12477. PMID: 25469569.
Tustumi F, Bernardo WM, da Rocha JR, et al. Esophageal achalasia: a risk factor for carcinoma. Arq Bras Cir Dig. 2017;30(3):194-198. DOI: 10.1590/0102-6720201700030011. PMID: 29019545.
Csendes A, Braghetto I, Burdiles P, et al. Very late results of esophagomyotomy for patients with achalasia: clinical, endoscopic, histologic, manometric, and acid reflux studies in 67 patients for a mean follow-up of 190 months. Ann Surg. 2006;243(2):196-203. DOI: 10.1097/01.sla.0000197469.13464.52. PMID: 16432352.
Patel DA, Lappas BM, Vaezi MF. An overview of achalasia and its subtypes. Gastroenterol Hepatol (N Y). 2017;13(7):411-421. PMID: 28804443.
Li QL, Chen WF, Zhou PH, et al. Peroral endoscopic myotomy for the treatment of achalasia: a clinical comparative study of endoscopic full-thickness and circular muscle myotomy. J Am Coll Surg. 2013;217(3):442-451. DOI: 10.1016/j.jamcollsurg.2013.04.033. PMID: 23890841.